Advanced Cell Technology (OTC BB: ACTC) IRB approval to treat dry-AMD by hESC-derived retinal pigment epithelial (RPE) cells
Embryonic Stem Cell Clinical Trial for Macular Degeneration
Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the P1/2 clinical trial for dry age-related macular degeneration (dry AMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.
- The P1/2 trial for dry AMD is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD. The trial will ultimately enroll 12 patients, with cohorts of 3 patients each in an ascending dosage format. The Jules Stein Institute at the University of California, Los Angeleshas also received IRB approval.
Related Posts
Categories: ACTC.OB, Advanced Cell Technology
